An observational study in Down Syndrome, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-01-31.
Sponsored by University of Colorado, Denver · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Down Syndrome by University of Colorado, Denver — 4 open to participants now, 4 under way, 1 of them phase 3. Down Syndrome · University of Colorado, Denver.
Among the 12 studies in Down Syndrome by University of Colorado, Denver, this one is the only one that started in 2013, is one of 5 observational ones, and was the 2nd registered.
439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.
Browse Down Syndrome studies →4 of the 12 studies in Down Syndrome by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 6–22
University of Colorado, Denver · Sites in United States
Ages 18–50 · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 6 mo–89 yrs · Healthy volunteers
By country, each count listing its studies:
Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100,000 is above the median of 158 across 145 observational studies indexed under Down Syndrome.
Median enrollment 47 across the 7 interventional studies, 800 across the 5 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Down Syndrome by University of Colorado, Denver, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to develop a registry for Down syndrome (DS) to facilitate research participation by individuals with Down syndrome.
DS-Connect® is an online survey tool designed to collect demographic data and health information from individuals with DS. It is open to all people with Down syndrome.
The purposes of DS-Connect® are:
The DS-Connect® Registry is a unique resource that enables communication and sharing of ideas among the NIH, individuals with DS and their families, national and international organizations interested in DS, and a diverse group of professionals involved in scientific research and medical care benefiting the population with DS. By providing information on their demographics, health histories, medications, and other relevant biomedical information, self-advocates and their families provide an unprecedented view of this genetic condition that can inspire new scientific inquiries, clinical research, and clinical trials specifically serving this population. For example, the DS-Connect® dataset has led to an increasing appreciation of the prevalence of many co-occurring conditions affecting individuals with DS across the lifespan, thus providing the rationale for the launch of the NIH INCLUDE Project (INvestigation of Co-occurring conditions across the Lifespan to Understand Down SyndromE). Conversely, self-advocates and their families participating in DS-Connect® benefit in several ways, including valuable comparison of their health histories with metrics from the entire cohort, access to key resources (e.g., list of active clinical trials), as well as opportunities for participation in human research protocols, including clinical trials testing new interventions to address diverse aspects of this condition. In turn, the DS-Connect® dataset informs both NIH and the research community on the need to support specific research areas, while also providing an avenue for researchers to promote recruitment into their studies. Altogether, DS-Connect® provides a multimodal platform for exchange of information and ideas across all key stakeholders, assuring that scientific research in this field is attuned to the needs of the community.
A person with DS or a family member or caregiver can register directly through the DS-Connect® website at their convenience. They may learn of the Registry from many sources including partner advocacy groups, government and healthcare organizations, or other families who are members in the Registry. The DS-Connect® platform readily captures participant information using condition-specific surveys.
All information is provided by the participant or representative for the participant via the web-based Registry. There are no in-person visits required for registration.
Individuals with DS (including those with mosaic DS and partial trisomy 21).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
No individuals with DS will be excluded from taking part in DS-Connect based on age, race, ethnicity, or gender.
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals who have a diagnosis of complete trisomy 21, translocation Down syndrome or mosaic Down syndrome.
To determine the prevalence of the various co-occurring conditions in Down syndrome.
Participants in DS-Connect® will complete health history surveys regarding medical diagnoses and can update the surveys annually or whenever their health changes.
Time frame: Through study completion, up to 10 years
Facilitate participation in research for individuals with DS who may be eligible for research studies or new clinical trials.
Participants may choose to hear about Down syndrome research studies that may be relevant to their co-occurring conditions.
Time frame: Through study completion, up to 10 years
Enable aggregate data sharing from individuals with Down syndrome.
Consented individuals will have their de-identified data shared with the INCLUDE Data Hub to enable researchers to understand etiology, natural history, and/or treatment effectiveness in Down syndrome.
Time frame: Through study completion, up to 10 years
Plan to share: Yes — IPD will be available to other researchers through the INCLUDE Data Hub.
No publications or documents are linked to this record.
Started Sep 2013 (actual). Primary completion is estimated for Jun 2035, 261 months after the start.
Of 40 non-industry observational studies under Down Syndrome, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 261 months is above that.
Counting every sponsor, half of 55 studies reached it within 34 months; a quarter within 19 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →